David Ramstad, MD
Internal Medicine · Suffolk, VANPI 1477516748
Payments from drug & device makers
Across 1,195 payments — averaging $4823.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2.4M
- Novartis$906K
- Pfizer$763K
- Modernatx, Inc.$524K
- Sanofi Pasteur Inc.$344K
- Bavarian Nordic A/s$237K
- plus $597K from 11 others
Across 1 payment — averaging $650.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$650
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 38 | $2,393,456 |
| Novartis | 15 | $906,281 |
| Pfizer | 92 | $762,510 |
| Modernatx, Inc. | 403 | $524,001 |
| Sanofi Pasteur Inc. | 26 | $344,265 |
| Bavarian Nordic A/s | 67 | $237,418 |
| Janssen Research & Development, LLC | 316 | $220,507 |
| Kowa Research Institute, Inc. | 36 | $81,649 |
| AstraZeneca | 7 | $76,189 |
| Esperion Therapeutics, Inc. | 151 | $73,631 |
| Eli Lilly | 4 | $47,876 |
| Sanofi US Services Inc. | 10 | $42,547 |
| GSK | 15 | $25,470 |
| Gilead | 3 | $15,673 |
| Regeneron | 2 | $6,325 |
| Novo Nordisk AS | 1 | $5,000 |
| Seqirus USA Inc | 9 | $1,872 |
How this compares
$5,764,668 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 164 | $199,666 |
| OzempicSemaglutide | 106 | $115,416 |
| TrulicityDulaglutide | 50 | $52,961 |
| JanuviaSitagliptin Phosphate | 40 | $40,801 |
| XareltoRivaroxaban | 17 | $27,256 |
| RybelsusSemaglutide | 13 | $22,491 |
| EliquisApixaban | 30 | $21,608 |
| FarxigaDapagliflozin Propanediol | 11 | $17,657 |
| Repatha SureclickEvolocumab | 16 | $15,145 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $11,578 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $9,827 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,996 |
| Atorvastatin Calcium | 849 | $7,900 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $7,385 |
| Dexlansoprazole DrDexlansoprazole | 15 | $4,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $762,510 | $21,60830 claims |
| AstraZenecaFarxiga | $76,189 | $17,65711 claims |
| GSKBreo Ellipta | $25,470 | $8,99616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Suffolk
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
- Lawrence SchwartzRichmond$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.